Activation of Raf-1 suppresses integrin activation, potentially through the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2). However, bulk ERK1/2 activation does not correlate with suppression. PEA-15 reverses suppression of integrin activation and binds ERK1/2. Here we report that PEA-15 reversal of integrin suppression depends on its capacity to bind ERK1/2, indicating that ERK1/2 function is indeed required for suppression. Mutations in either the death effector domain or C-terminal tail of PEA-15 that block ERK1/2 binding abrogated the reversal of integrin suppression. Furthermore, we used ERK/p38 chimeras and site-directed mutagenesis to identify ERK1/2 residues required for binding PEA-15. Mutations of residues that precede the α6 helix and within the mitogen-activated protein kinase insert blocked ERK2 binding to PEA-15, but not activation of ERK2. These ERK2 mutants blocked the ability of PEA-15 to reverse suppression of integrin activation. Thus, PEA-15 regulation of integrin activation depends on its binding to ERK1/2. To directly test the role of ERK1/2 localization in suppression, we enforced membrane association of ERK1 and 2 by joining a membrane-targeting CAAX box sequence to them. Both ERK1-CAAX and ERK2-CAAX were membrane-localized and suppressed integrin activation. In contrast to suppression by membrane-targeted Raf-CAAX, suppression by ERK1/2-CAAX was not reversed by PEA-15. Thus, ERK1/2 are the Raf effectors for suppression of integrin activation, and PEA-15 reverses suppression by binding ERK1/2.

Changes in integrin affinity for ligand (activation) play a central role in integrin functions such as cell adhesion, migration and assembly of the extracellular matrix (1). Activation is transduced by a complex series of cellular signaling pathways that modify the interaction of cytoplasmic proteins, such as talin (2), with integrin cytoplasmic domains (3). Integrin activation is a tightly regulated event, suggesting the existence of pathways that can both promote and suppress integrin activation. One such pathway leads to a marked reduction in integrin affinity as a consequence of activation of the small GTP-binding protein H-Ras and its downstream effector kinase Raf-1 (4). Inhibition of extracellular signal-regulated kinases 1 and 2 (ERK1/2) by the phosphatase MKP-1 (4) or but not MKP-3 (6) reduces integrin suppression, indicating that ERK1/2 are likely downstream effectors of H-Ras/Raf-1-mediated suppression. R-Ras, a small GTP-binding protein with substantial homology to H-Ras, has the opposite effect of H-Ras on the integrins (i.e. promoting integrin activation) (5). Thus, the interplay between R-Ras and H-Ras could act as a rheostat for integrin function. Certain chimeras of H-Ras/R-Ras proteins that retain the ability to suppress integrin activation were weak activators of ERK1/2 (6). Moreover, inhibition of bulk ERK1/2 activation by use of a MEK inhibitor or transfection of MKP-3 does not abolish suppression (6). These observations suggest that Ras-mediated integrin suppression may be independent of ERK1/2 or that low level ERK1/2 activation in particular cellular areas is sufficient for suppression.

Interest in further characterizing the intracellular signaling pathways that regulate integrin activation led to the isolation of a small protein, previously designated PEA-15 (7, 8). Cellular expression of PEA-15, a 15-kDa protein expressed in a broad range of tissues and enriched in astrocytes (9), prevents activated H-Ras/Raf-1-mediated integrin suppression (8). PEA-15 binds ERK1/2 but does not inhibit ERK1/2 kinase activity or activation; instead, PEA-15 redirects the output of
ERK1/2 signaling by altering the subcellular localization of ERK1/2 (10). Thus, it is plausible that PEA-15 may be one of a class of proteins capable of modulating ERK1/2 function and thereby integrin suppression. PEA-15 is composed of an N-terminal death effector domain (DED), a protein interaction module more commonly found in proteins that regulate apoptosis, and a C-terminal tail of irregular structure. NMR “foot-printing” and mutagenesis studies identified residues in both the DED and tail that are required for ERK1/2 binding (11). In this study, we explored the relationship between PEA-15 interaction with ERK1/2 and the role of ERK1/2 in integrin suppression. Single point mutations in either the DED or tail of PEA-15, which inhibit interaction with ERK1/2, resulted in a concomitant loss of the ability of PEA-15 to reverse suppression of integrin activation. Furthermore, we used a series of ERK/p38 chimeras (12, 13) in combination with site-directed mutagenesis to identify ERK1/2 residues required for PEA-15 binding. Point mutation of residues preceding the aG helix or within the MAPK insert blocked the capacity of ERK2 to bind PEA-15 but did not adversely effect ERK2 phosphorylation. Cellular expression of each of these mutant ERKs blocked the ability of PEA-15 to reverse suppression of integrin activation. Thus, the capacity of PEA-15 to regulate integrin activation depends on its binding to ERK1/2. To directly test the role of ERK1/2 in suppression, we enforced membrane association of ERK1 and 2 by joining a membrane-targeting CAAX box sequence to them. Both ERK1-CAAX and ERK2-CAAX were membrane-localized and suppressed integrin activation. In contrast to suppression by membrane-targeted Raf-CAAX, suppression by ERK1/2-CAAX was not reversed by PEA-15. Thus, ERK1/2 are the Raf effectors that lead to suppression of integrin activation, and PEA-15 reverses suppression by binding ERK1/2.

MATERIALS AND METHODS

Cell Culture—Chinese hamster ovary (CHO) cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 1% nonessential amino acids (Sigma), 1% glutamine (Sigma), and 1% penicillin and streptomycin (Sigma).

Antibodies, Reagents, and cDNA Constructs—The activating β1 antibody 9E6G7 was purchased from Pharmingen. The anti-ERK1 and anti-ERK2, anti-Ras, anti-RhoGDi, and anti-phospho-ERK1/2 antibodies were purchased from Santa Cruz Biotechnology, Inc. The mouse monoclonal anti-HA antibody (12CA5) and anti-integrin β1 (7E2) were as described (4). Anti-lamin A/C was a generous gift from Dr. Larry Gerace (The Scripps Research Institute). Anti-PEA-15 (3099) was previously described (14). All PEA-15 mutants were generated by using the QuikChange kit (Stratagene) using HA-PEA-15-pcDNA3 as template. ERK2 mutants were generated by the same strategy using HA-ERK2-pcDNA3 as template. All constructs were confirmed by DNA sequencing. The p38/ERK1 chimeric constructs have been described (12). The p38/ERK2 constructs were gifts from Dr. Melanie Cobb (13). The HA-ERK1-CAAX-pEF and HA-ERK1-SAAX-pEF constructs were as described (15). Kinase-dead HA-ERK1(K71R)-CAAX-pEF was generated by using the QuikChange kit (Stratagene) using HA-ERK1-CAAX-pEF as template. GST-PEA-15 expression vector was constructed by subcloning the full-length PEA-15 from HA–PEA-15-pcDNA3 into the pGEX-2T vector (Amersham Biosciences). Purification of recombinant 3Fn-(9–11) from the pGEX expression vector encoding Type III repeats 9–11 of fibronectin was previously described (16).

In Vitro PEA-15 Pull-down Assay—CHO cells were transfected with p38/ERK1/2 chimeras using LipofectAMINE reagents as per the manufacturer’s protocol (Invitrogen). 40–48 h post-transfection, cells were washed with 1× phosphate-buffered saline (pH 7.4) and lysed in lysis buffer (20 mM HEPES, pH 7.2, 2 mM MgCl₂, 2 mM EGTA, and 1 mM phenylmethylsulfonyl fluoride). Total lysates were homogenized with binding buffer (20 mM HEPES, pH 7.2, 1% Nonidet P-40, 10% glycerol, 2 mM EGTA, 2 mM MgCl₂) and centrifuged at 12,000 rpm for 10 min. The cleared lysates (supernatant) were mixed with 10 μl of GSH-Sepharose-bound GST-PEA-15 for 2 h at 4 °C. After washing four times with binding buffer, bound proteins were eluted with SDS sample buffer and resolved by SDS-PAGE under reducing conditions.

**Fig. 1. PEA-15 regulates integrin activation.** A, PEA-15 null (KO) or wild type (WT) mouse fibroblasts were incubated at room temperature for 30 min in the presence or absence of TPA (100 nM). The cells were suspended, and the binding of 3Fn-(9–11) was assayed by two-color flow cytometry as described under “Materials and Methods.” In the left panel, TPA elicited an increase in 3Fn-(9–11) binding in wild type cells but not in the null cells. However, when the cells were transfected with PEA-15, both null and wild type exhibited similarly enhanced 3Fn-(9–11) binding in response to TPA (right panel). B, cell lysates from the untransfected cells in A were fractionated by SDS-PAGE and immunoblotted (IB) with antibodies against phospho-ERK (pERK) or total ERK. Note the similar degrees of TPA-induced phosphorylation of ERK in the wild type and null cells. C, the cell lysates from A were immunoblotted for the expression of the HA epitope to verify similar quantities of recombinant PEA15 expression in all of the transfected cell preparations.

**Materials and Methods**

Cell Culture—Chinese hamster ovary (CHO) cells were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen), 1% nonessential amino acids (Sigma), 1% glutamine (Sigma), and 1% penicillin and streptomycin (Sigma).

Antibodies, Reagents, and cDNA Constructs—The activating β1 antibody 9E6G7 was purchased from Pharmingen. The anti-ERK1 and anti-ERK2, anti-Ras, anti-RhoGDi, and anti-phospho-ERK1/2 antibodies were purchased from Santa Cruz Biotechnology, Inc. The mouse monoclonal anti-HA antibody (12CA5) and anti-integrin β1 (7E2) were as described (4). Anti-lamin A/C was a generous gift from Dr. Larry Gerace (The Scripps Research Institute). Anti-PEA-15 (3099) was previously described (14). All PEA-15 mutants were generated by using the QuikChange kit (Stratagene) using HA-PEA-15-pcDNA3 as template. ERK2 mutants were generated by the same strategy using HA-ERK2-pcDNA3 as template. All constructs were confirmed by DNA sequencing. The p38/ERK1 chimeric constructs have been described (12). The p38/ERK2 constructs were gifts from Dr. Melanie Cobb (13). The HA-ERK1-CAAX-pEF and HA-ERK1-SAAX-pEF constructs were as described (15). Kinase-dead HA-ERK1(K71R)-CAAX-pEF was generated by using the QuikChange kit (Stratagene) using HA-ERK1-CAAX-pEF as template. GST-PEA-15 expression vector was constructed by subcloning the full-length PEA-15 from HA–PEA-15-pcDNA3 into the pGEX-2T vector (Amersham Biosciences). Purification of recombinant 3Fn-(9–11) from the pGEX expression vector encoding Type III repeats 9–11 of fibronectin was previously described (16).

In Vitro PEA-15 Pull-down Assay—CHO cells were transfected with p38/ERK1/2 chimeras using LipofectAMINE reagents as per the manufacturer’s protocol (Invitrogen). 40–48 h post-transfection, cells were washed with 1× phosphate-buffered saline (pH 7.4) and lysed in lysis buffer (20 mM HEPES, pH 7.2, 2 mM MgCl₂, 2 mM EGTA, and 1 mM phenylmethylsulfonyl fluoride). Total lysates were homogenized with binding buffer (20 mM HEPES, pH 7.2, 1% Nonidet P-40, 10% glycerol, 2 mM EGTA, 2 mM MgCl₂) and centrifuged at 12,000 rpm for 10 min. The cleared lysates (supernatant) were mixed with 10 μl of GSH-Sepharose-bound GST-PEA-15 for 2 h at 4 °C. After washing four times with binding buffer, bound proteins were eluted with SDS sample buffer and resolved by SDS-PAGE under reducing conditions.
Bound proteins were visualized by Western blotting with anti-HA to detect transfected chimeric proteins. The same protocol was used for GST-PEA-15 pull-down of HA-ERK1-CAAX, HA-ERK1-SAAX, and HA-ERK1(K71R)-CAAX.

Wild-type and mutant ERK2 contained in a NpT7–5 vector (17) were expressed in vitro using the TNT T7 coupled reticulocyte lysate system (Promega) in the presence of [35S]methionine. GST-PEA-15 bound to glutathione-agarose beads (Sigma) was incubated with 35S-labeled wild-type and mutant ERK2 proteins in 150 mM HEPES (pH 7.4), 50 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and 10% glycerol. Samples were incubated for 2 h at 4 °C and then washed three times with 0.5 ml of the same buffer. The bound proteins were separated on 16% Tris-Tricine gels and visualized by phosphorimaging.

Flow Cytometry—Analytical two-color flow cytometry was carried out as previously described (4). Briefly, CHO cells were transfected with GFP (0.1 μg) as transfection marker and a combination of HA-ERK2-pcDNA3, ERK2 mutants in the pcDNA3 vector, H-Ras(G12V)-pcDNA3, and HA-PEA-15-pcDNA3. A total of 5 μg of DNA was used for each transfection. Transient transfections were carried out using LipofectAMINE Plus reagent as per the manufacturer’s protocol (Invitrogen). 24 h post-transfection, cells were harvested and analyzed for transfection efficiency (GFP) and integrin binding to 3Fn-(9–11). In
brie, for each transfection, harvested cells were divided into three tubes. The three preparations were used to assay for binding to 3Fn-(9–11) alone, binding in the presence of EDTA (10 mM), or in the presence of 9EG7 (10 ng/μl). All incubation and washes were carried out using 1× Tyrode buffer (10 mM HEPES, 10 g of NaCl, 1.015 g of NaHCO3, 0.195 g of KCl, 1 mg/ml dextrose, 1 mg/ml bovine serum albumin, 1 mM CaCl2, 1 mM MgCl2, pH 7.4). Cells were first incubated with EDTA or 9EG7 for 10 min at room temperature, and 3Fn-(9–11) was then added to all samples and allowed to incubate at room temperature for 20 min. After washing twice with 1× Tyrode buffer, cells were incubated with streptavidin-R-phycocerythin (20 ng/μl) on ice for 20 min. Propidium iodide (1 ng/μl) was added to each sample for the last 5 min. Samples were washed twice before analysis. Integrin activation was quantified as an activation index (AI) as previously defined (4). AI = 100 * (F – Fm₀)/(Fm – Fm₀), where F represents the geometric mean fluorescence (GMF) of 3Fn-(9–11) binding alone, F₀ is the GMF of 3Fn-(9–11) binding in the presence of EDTA (10 mM), and Fm₀ is the GMF of 3Fn-(9–11) binding in the presence of 9EG7. The percentage of suppression was calculated as 100 * (AI – AI°)/AI°, where AI° is the activation index of the mock-transfected cells, and AI is the activation index in the presence of a transfected cDNA. The percentage of reversal of suppression was calculated as 100 * (AI – AI°)/AI°, in which AI is the activation index of the control cells, and AI° is the activation index in the presence of a transfected rescuing cDNA. In addition to FACS analysis, the cell lysate of each transfection was analyzed for expression of the transfected constructs and phosphorylation of ERK1/2 by immunoblotting. The same protocol was used to assay integrin suppression by Raf-CAAX, HA-ERK1-CAAX, HA-ERK1-SAAAX, and HA-ERK1(K71R)-CAAX.

PEA-15 Knockout Fibroblasts—PEA-15 knockout fibroblasts derived from PEA-15 null mice (18) or wild-type fibroblasts were transiently transfected with cDNA encoding a reporter, GFP (0.3 μg), and HA PEA-15-pcDNA3 (3 μg). As a control, knockout and wild-type fibroblasts were transiently transfected with GFP and empty pcDNA3 vector. Transient transfections were carried out using LipofectAMINE and Plus reagents per the manufacturer's protocol (Invitrogen). 24 h post-transfection, cells were incubated in 0.5% serum Dulbecco's modified Eagle's medium overnight. After stimulation with 12-0-tetradecanoylphorbol-13-acetate (TPA) (100 nM) for 1 h, cells were harvested and analyzed for transfection efficiency (GFP) and integrin binding to 3Fn-(9–11) by two-color flow cytometry as described above. Additionally, cell lysates were analyzed for expression of transfected HA-PEA-15 and phosphorylation of ERK1/2 induced by TPA treatment.

Subcellular Fractionation—CHO cells were transfected as described above with HA-ERK1-CAAX, HA-ERK1-SAAAX, or HA-ERK1(K71R)-CAAX. 24 h post-transfection, cells were harvested in 0.5 ml of lysis buffer (20 mM HEPES-KOH, pH 7.5, 1.5 mM MgCl2, 5 mM KCl, 0.2 mM NaVO4, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 mM phenylmethyl-sulfonyl fluoride). After a 10-min incubation on ice to allow for swelling, cells were disrupted using 40 strokes in a Dounce homogenizer. A fraction of the total cell lysate was saved prior to centrifugation at 2000 rpm for 10 min to pellet the nuclei. The supernatant was subjected to additional centrifugation at 13,000 rpm for 30 min to pellet the membrane fraction. The result supernatant is the cytosolic fraction. The membrane pellet was extracted at 4 °C with lysis buffer containing 1% Nonidet P-40. After centrifuging at 14,000 rpm for 10 min, the membrane-soluble supernatant was removed, and the insoluble pellet was resuspended in 100 μl of 1× SDS-PAGE buffer. Total lysate, membrane-soluble, and cytosolic fractions were analyzed for protein expression by immunoblot.
RESULTS

Mutations of PEA-15 That Block ERK1/2 Binding Abrogate Reversal of H-Ras/Raf-1-dependent Integrin Suppression—PEA-15 binds ERK1/2 and blocks the ability of activated H-Ras to suppress activation of recombinant chimeric integrins. To determine whether PEA-15 affects the activation of native integrins, we assessed the effects of PEA-15 on activation of integrins. Both wild type and PEA-15 knockout fibroblasts bound to the recombinant cell-binding domain of fibronectin (3Fn-(9–11); Fig. 1A) to a similar extent. In contrast, when we stimulated integrin activation with TPA, wild type fibroblasts showed an increase in specific 3Fn-(9–11) binding (Fig. 1A), but the PEA-15 knockout cells (Fig. 1A) did not alter 3Fn-(9–11) binding. The TPA was active in both cell contexts, since it activated ERK MAPK (Fig. 1B). These data suggested the possibility that the absence of PEA-15 rendered the integrins resistant to activation, possibly because TPA also activated the ERK pathway leading to concomitant suppression. To test this possibility, we reconstituted the knockout cells with PEA-15, leading to restoration of TPA binding to recombinant fibronectin (3Fn-(9–11) binding (Fig. 1A), but the PEA-15 knockout cells (Fig. 1A) did not alter 3Fn-(9–11) binding. The TPA was active in both cell contexts, since it activated ERK MAPK (Fig. 1B). These data suggested the possibility that the absence of PEA-15 rendered the integrins resistant to activation, possibly because TPA also activated the ERK pathway leading to concomitant suppression. To test this possibility, we reconstituted the knockout cells with PEA-15, leading to restoration of TPA activation of 3Fn-(9–11) binding. In contrast, transfection of wild type cells with PEA-15 had no additional effect on responsiveness to TPA (Fig. 1A). Comparable expression of transfected HA-PEA-15 was observed (Fig. 1B) in both cell types. Thus, endogenous PEA-15 can regulate the response of cellular integrins to agonists.

To explore the role of the PEA-15 interaction with ERK1/2 in modulating integrin activation, we exploited the recently determined structure of PEA-15 (11). PEA-15 consists of an N-terminal DED composed of six antiparallel amphipathic α-helices closely packed around a central hydrophobic core, followed by a long C-terminal tail (Fig. 2A). The C-terminal tail is irregularly structured with the exception of residues 120–123, which form a single turn of 310-helix. NMR “footprinting” and site-directed mutagenesis have established that residues in both the DED and the tail are involved in ERK1/2 binding (10, 11). In particular, one mutation in the DED (D74A) and three mutations in the tail (I121R, L123R, and K129E) strongly inhibit binding to ERK1/2. The D74A mutant has previously
been shown to block the effects of PEA-15 on integrin activation (8). Similarly, each of the three new mutants that block ERK1/2 binding also abrogated the effects of PEA-15 on integrin activation (Fig. 2B). Mutations within PEA-15 that were only partially defective for ERK1/2 binding (11) either partially (K122E) or fully (E18R) reversed integrin suppression, which correlates with the relative defect in PEA-15/ERK2 interaction (11) (Fig. 2B). These observations were not a consequence of differential expression levels of the mutants (Fig. 2C). Furthermore, ERK1/2 was phosphorylated when each of the mutants was co-transfected with H-Ras(G12V) (Fig. 2C). Thus, the capacity of PEA-15 to bind to ERK1/2 closely correlates with its ability to reverse H-Ras suppression of integrin activation.

Identification of ERK1/2 Mutants That Fail to Bind PEA-15—The foregoing experiments showed that PEA-15 mutations that strongly inhibit ERK1/2 binding also abrogated the capacity of PEA-15 to block suppression of integrin activation. However, these mutations may perturb other functions of PEA-15 in addition to ERK1/2 binding. To exclude this possibility, we sought to identify mutations in ERK1/2 that disrupt PEA-15 binding and to learn whether they block the effect of PEA-15 on integrin activation. PEA-15 binds specifically to ERK1/2 and not to the related MAPKs p38 or c-Jun N-terminal kinase (10). Furthermore, there is a high degree of sequence identity between ERK1 and ERK2. To map the regions of ERK1/2 involved in PEA-15 binding, we employed a number of existing ERK/p38 chimeras (Fig. 3A) used previously to identify domains important for interacting with upstream kinases, target substrates, and phosphatases (12, 13, 21). The three-dimensional structures of ERK1/2 and p38 are similar (22), and the chimeras contain selected intact structural subdomains from each enzyme. Binding to PEA-15 was assessed using lysates from CHO cells transfected with HA-tagged ERK/p38 chimeras incubated with immobilized GST-PEA-15 (Fig. 3, B and C). A chimera possessing the first four subdomains and the C-terminal loop of p38, which form the N-terminal half of the protein, retained the ability to bind PEA-15 (chimera PIVECTP in Fig. 3B). In contrast, studies of C-terminal chimeras of ERK1 and p38 indicated that only a chimera containing subdomains X and XI of ERK1 (chimera EXIP in Fig. 3C) retained binding activity. Conversely, insertion of subdomains X and XI of p38 into ERK1 abolished binding (chimera EVIII PXIE in Fig. 3C). These data indicate that regions localized within the C-terminal domain of ERK, subdomains X and XI in particular, are required for PEA-15 binding.

ERK1/2 have a characteristic protein kinase structure with an N-terminal domain rich in β-sheet and a C-terminal domain that is mostly α-helical (23, 24). Structural features unique to MAPK are an insertion of ~30 residues between subdomains X and XI and a C-terminal extension that folds back over the N-terminal domain such that the N and C termini are in close proximity. Subdomains X and XI of ERK1/2 encompass the αG helix and the α1L14-α2L14 loop of the MAPK insert, which form a distinct, surface exposed region of the protein situated below the phosphorylation lip (Fig. 4A). Furthermore, this region displays considerable sequence and structural diversity among MAPK family members (23, 25, 26) yet is highly conserved between ERK1 and ERK2 (Fig. 4B). Thus, this diversity could account for the failure of p38 and c-Jun N-terminal kinase to bind to PEA-15. A series of point mutations were introduced into the αG helix and MAPK insert of ERK2 to further investigate the importance of this region for the interaction with PEA-15. Mutations at five positions, Tyr231, Leu232, Lys257, and Arg259, substantially reduced or abrogated binding to PEA-15 (Fig. 4C). These residues are located at the start of the αG helix and in the α2L14 helix of the MAPK insert (Fig. 5A). Alteration of residues in the α1L14 helix (Asn251), in the α1L14-α2L14 loop (Ile254 and Leu256), and at the end of the α2L14 helix (Asn260, Leu263, and His267) had no effect on binding to PEA-15 (Fig. 5A and data not shown). This localizes part of the PEA-15 binding site to the loop preceding and start of the αG helix and to the beginning of the α2L14 helix within the MAPK insert (Fig. 5B). An essential role for this region of ERK2 has also recently been demonstrated for the interaction with its upstream activators, MEK1/2 (27).

ERK2 Mutants That Fail to Bind PEA-15 Block PEA-15 Reversal of Integrin Suppression—As described above, we identified several point mutations in ERK2 that blocked binding to PEA-15. Transfection of cells with wild-type ERK2 or any of the mutants failed to suppress or enhance the binding of 3Fn(9–11) to CHO cells, although all of the mutants were well expressed (Fig. 6). Furthermore, when these mutants were co-transfected with H-Ras(G12V), they failed to enhance or reverse suppression (Fig. 7). Moreover, each of the mutants was phosphorylated to a similar extent to wild-type ERK2 and did not interfere with the phosphorylation of endogenous ERK1/2 (data not shown). Thus, expression of these ERK2 mutants neither suppressed integrin activation; nor did they influence the ability of activated H-Ras to suppress it.

We then examined the effect of these ERK2 mutants on the...
Fig. 6. Expression of ERK2 mutants has no effect on integrin activation. 
A, CHO cells were transiently transfected with expression vectors encoding GFP as transfection reporter and the indicated ERK2 variants. Cells were harvested and analyzed by two-color FACS for transfected cells (GFP +) and 3Fn-(9–11) binding. Shown on the ordinate is mean activation index ± S.E. of three independent experiments. A vector-transfected cell had the same activation index as that transfected with wild type ERK2 (data not shown). B, expression of the ERK2 variants was assessed by immunoblotting with anti-ERK2.

Fig. 7. Expression of ERK2 mutants has no effect on H-Ras(G12V)-dependent integrin suppression. 
A, CHO cells were transiently transfected with expression vectors encoding GFP as transfection reporter, H-Ras(G12V), and the indicated ERK2 variants. Cells were harvested and analyzed by two-color FACS for GFP expression and 3Fn-(9–11) binding. Shown on the ordinate is mean suppression of integrin activation ± S.E. from three independent experiments. Transfection with wild-type or mutant ERK2 variants had little effect on the ability of H-Ras(G12V) to induce suppression of integrin activation. A vector-transfected cell, co-transfected with H-Ras(G12V), exhibited the same activation index as the cell transfected with wild type ERK2 and H-Ras(G12V) (data not shown). B, ERK2 expression was assessed by immunoblotting with anti-ERK2. Each of the mutants was well expressed.

Membrane-targeted ERK1/2 Suppresses Integrin Activation—PEA-15 binding to ERK1/2 prevents the nuclear localization of the activated kinases (10), suggesting that PEA-15 might reverse integrin suppression by changing the cellular localization of ERK1/2. To test this idea, we examined the effects of enforcing a membrane localization of ERK1/2 on integrin activity. Transfection of cells with a chimera of the membrane-targeting sequence of H-Ras with ERK1 (ERK1-CAAX) resulted in profound suppression of integrin activation (Fig. 9A) and membrane localization of the ERK1 (Fig. 9C). Membrane localization was responsible for this effect, since a Ser substitution for the Cys of the CAAX box (ERK1-SAAX) was neither membrane-localized (Fig. 9C) nor suppressive (Fig. 9A). Integrin suppression required the kinase function of ERK1, since an ERK1(K71R)-CAAX construct, which lacks kinase activity, was much less suppressive (Fig. 9A) although it was membrane-localized (Fig. 9C). All three constructs were expressed at similar levels (Fig. 9B), and a corresponding series of ERK2 constructs showed identical effects on integrins to the ERK1 constructs (data not shown). Thus, membrane localization or ERK1/2 leads to suppression of integrin activation.

PEA-15 Fails to Reverse Suppression Mediated by ERK1-CAAX—Because enforced membrane localization of ERK1/2 led to suppression of integrin activation and PEA-15 changes the cellular localization of ERK1/2, PEA-15 might reverse suppression by displacing ERK1/2 from the membrane. We were unable to detect enrichment of activated ERK1/2 in our bulk membrane preparations. However, we reasoned that if the capacity of PEA-15 to reverse suppression depended on its ability to bind and relocalize ERK1/2, then PEA-15 should fail
to reverse suppression mediated by membrane-tethered ERK1/2. Indeed, co-transfection of PEA-15 with ERK1-CAAX did not reverse suppression of integrin activation (Fig. 10A). In sharp contrast, PEA-15 completely reversed suppression mediated by membrane-tethered Raf-CAAX (Fig. 10A) although PEA-15 was equally well expressed in both transfections (Fig. 10B). The ERK1-CAAX bound PEA-15 to a similar extent as wild type ERK1 (Fig. 10C). Thus, when ERK is membrane-tethered, PEA-15 fails to reverse suppression of integrin activation.

**DISCUSSION**

Rapid modulation of ligand-binding affinity (activation) is a central property of the integrin family of adhesion receptors and has important functional consequences in development, homeostasis, the immune response, and maintenance of tissue integrity (1). The Ras family of small GTP-binding proteins and their downstream effectors are key players in regulating integrin activation. Activated H-Ras can suppress integrin activation via its downstream effector kinase, Raf-1, to control cell morphology, migration, and assembly of the extracellular matrix (4). This suppression could be mediated by the ERK1/2 MAPK pathway; however, bulk ERK1/2 activation does not correlate with suppression (6). The small DED-containing protein, PEA-15, reverses H-Ras suppression of integrin activation and binds to ERK1/2, altering the subcellular localization of ERK1/2 and consequently the outcome of the ERK1/2 signaling cascade (8, 10). Here we demonstrate that the ability of PEA-15 to reverse suppression lies in its capacity to bind ERK1/2, indicating that ERK1/2 function is required for suppression. Our results further suggest that reversal of suppression by PEA-15 is due to inhibition of an ERK1/2 function, possibly by preventing access to membrane-associated substrates, rather than the acquisition of integrin-activating functions by the PEA-15-ERK1/2 complex.

The recently determined three-dimensional structure and mutational analysis of PEA-15 indicated the presence of two distinct binding sites for ERK, an acidic patch within the DED and a positively charged region within the C-terminal tail (11). Point mutations of individual residues in either of these regions of PEA-15 are sufficient to abrogate ERK1/2 binding and resulted in a loss of the capacity of PEA-15 to reverse H-Ras/Raf-1-dependent integrin suppression. Mutations in the C-terminal tail that block reversal (i.e. result in increased suppression of integrin activation) do not increase the phosphorylation of endogenous ERK2. The ERK2 mutations that block reversal (i.e. result in increased suppression of integrin activation) do not increase the phosphorylation of endogenous ERK2. The lower panel illustrates similar H-Ras(G12V) and PEA-15 expression in each cell lysate.

**FIG. 8.** Expression of ERK2 mutants that do not bind PEA-15 abolishes PEA-15 reversal of integrin suppression. A, CHO cells were transiently transfected with expression vectors encoding GFP as transfection reporter, H-Ras(G12V), PEA-15, and the indicated ERK2 variants. Cells were harvested and analyzed by two-color FACS for GFP expression and 3Fn(9–11) binding. Shown on the ordinate is mean percentage reversal of suppression ± S.E. from three independent experiments. ERK2 mutants that are lacking PEA-15 binding function (Y231E, L232E, and K257E) eliminated PEA-15 reversal of suppression. ERK2 mutants that exhibited a partial decrease in PEA-15 binding (K229D and R259E) showed decreased PEA-15-mediated reversal of integrin binding. B, cell lysates from the experiment described in A were fractionated by SDS-PAGE, and immunoblots were probed for ERK2, phospho-ERK1/2 (pERK), and the HA tag (HA). Note that phospho-ERK staining correlated with ERK expression of endogenous and transfected ERK2. The ERK2 mutations that block reversal (i.e. result in increased suppression of integrin activation) do not increase the phosphorylation of endogenous ERK2. The lower panel illustrates similar H-Ras(G12V) and PEA-15 expression in each cell lysate.
Lys257, and Arg259, substantially reduced or abrogated binding to PEA-15. Cellular expression of each of these ERK2 mutants blocked the ability of PEA-15 to reverse suppression of integrin activation. In the crystal structure of unphosphorylated ERK2, the activation loop extends from the active site and folds down upon the C-terminal domain, making contacts with residues from both the N terminus of helix H9251 and the MAPK insert (24). Although the mutations described here are located on the same surface of ERK2 as the active site, and residues Tyr231 and Leu232 are in close proximity to the activation loop, they have no adverse effect on ERK2 activation. Each of the mutants was expressed at level comparable with wild-type ERK2 and was phosphorylated to a similar extent, indicating that the mutants were correctly folded and able to serve as a substrate for MEK1/2. Importantly, these mutants blocked the effect of PEA-15 in the presence of endogenous wild-type ERK1/2. This implies that the mechanism of action of PEA-15 on integrins involves loss of ERK1/2 function rather than a novel function acquired by the PEA-15-ERK1/2 complex.

Several regions of MAPKs have been implicated in interactions with their substrates, activators, and regulators. A common docking groove has been identified in the C-terminal domain that functions as a general binding site (28–31) for many proteins that contain a conserved docking site sequence (32). This docking groove contains an acidic patch termed the CD domain (29) and adjacent hydrophobic patches (28) that accommodate the basic and hydrophobic motifs of the docking site sequences. However, this docking groove does not appear to play a role in the interaction with PEA-15, since ERK1/2 mutants that have been shown to abrogate binding by substrates and activators of ERK1/2 (T157E, T158D, D316N, and D319N) (29, 30) had no effect on PEA-15 binding (data not shown). These findings are consistent with the absence of a conserved docking site sequence within PEA-15. In contrast, recognition of the H9251 helix and MAPK insert of ERK1/2 by PEA-15 and MEK1/2 (27) highlights this region as a potential second common docking site. In addition to MAPKs, insertions in the kinase core between subdomains X and XI are found in the cyclin-dependent kinases and glycogen synthase kinase-3. X-ray crystal structures of cyclin-dependent kinase 2 and glycogen synthase kinase-3 have also recently demonstrated the functional importance of this region for these kinase families (33–35). Thus, the insertion in MAPKs and other structurally related serine/threonine kinases may act as a common docking site for a variety of regulatory proteins.

The dominant feature of the ERK1/2 binding surface of PEA-15 is the presence of two loci of opposite charge. The binding epitope within the PEA-15 DED is predominantly negatively charged, whereas the binding surface in the C-
terminal tail is composed of hydrophobic and positively charged residues (11). Thus, it is tempting to speculate that the DED of PEA-15 may contact the positively charged ERK1/2 binding surface provided by helix a and the MAPK insert. However, this region is not sufficient for PEA-15 binding, because a chimera containing subdomains X and XI of ERK1/2 in p38 is unable to bind PEA-15 (data not shown). This suggests that there are additional binding determinants required for PEA-15 binding. The tail of PEA-15 is also essential for ERK1/2 interaction and probably interacts with ERK1/2 at a second site, which may be discontinuous with the binding surface of the PEA-15 DED. The tail most likely contacts a negatively charged and/or hydrophobic surface given the deleterious effect of the PEA-15 mutations at Lys122, Lys125, and Lys129 on ERK1/2 binding.

In summary, we have shown that the capacity of PEA-15 to regulate integrin activation depends upon its binding to ERK1/2. In addition, we identified ERK1/2 mutants that are deficient for PEA-15 binding and prevent PEA-15 reversal of integrin suppression. These observations suggest that reversal of suppression is due to inhibition of an ERK1/2 function rather than the acquisition of integrin-activating functions by the PEA-15-ERK1/2 complex. Our data indicate that ERK1/2 function is critical for H-Ras/Raf-1 suppression of integrin activation. Whereas PEA-15 does not block ERK1/2 activation or its ability to phosphorylate several substrates (10), it does change the subcellular localization of ERK1/2 (10). It is plausible to consider a mechanism in which ERK1/2 is unavailable to phosphorylate critical substrates required for integrin suppression due to the interaction between ERK1/2 and PEA-15. PEA-15 may delocalize ERK1/2, blocking access of ERK1/2 to a location necessary for phosphorylation of substrates required for integrin suppression. For example, PEA-15 binding to ERK1/2 may remove ERK1/2 from a membrane-associated site such as focal adhesions (36) or an association with β-arrestin (37). The results described here suggest that ERK1/2 substrates at such sites will be critical for the suppression of integrin activation.

Acknowledgments—We gratefully acknowledge Drs. Melanie Cobb and Julie Wilsbacher for the gift of the ERK2-p38 chimeras.

REFERENCES


PEA-15 Binding to ERK1/2 MAPKs Is Required for Its Modulation of Integrin Activation

Fan-Li Chou, Justine M. Hill, Jyh-Cheng Hsieh, Jacques Pouyssegur, Anne Brunet, Angela Glading, Florian Überall, Joe W. Ramos, Milton H. Werner and Mark H. Ginsberg

doi: 10.1074/jbc.M309322200 originally published online September 23, 2003

Access the most updated version of this article at doi: 10.1074/jbc.M309322200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 36 references, 19 of which can be accessed free at
http://www.jbc.org/content/278/52/52587.full.html#ref-list-1